

THE TOP 10 MEDICATIONS AND THEIR OCULAR SIDE EFFECTS

Blair Lonsberry, MS, OD, MEd., FAAO
Professor of Optometry
Pacific University College of Optometry
blonsberry@pacificu.edu

1

Disclosures:

- Sun Pharmaceuticals: speakers bureau,
- Avellino: advisory board,
- Dompe: advisory board,
- RVL Pharmaceuticals: advisory board

2

Agenda

- Review of the most common systemic medications and their uses and associated ocular side effects:
 - Hydroxychloroquine (Plaquenil)
 - Tetracyclines
 - Amiodarone
 - Antidepressants
 - Steroids
 - Tamoxifen
 - Anti-histamines
 - Flomax
 - Topemax
 - Viagra/Cialis

3

What Factors Increase the Risk – Product Specific Variables

- **Amount of Drug Administered**
 - All medications have potential for toxicity if given in excessive amounts.
 - Long term use of therapeutic doses over time increase the risk of toxicity.
- **Nature of the Drug**
 - Ease of absorption into systemic circulation.
 - Ability to penetrate the blood-brain, blood-aqueous, and blood-retinal barriers.
 - Absorption by ocular tissues such as Melanin.
- **Route of Administration**
 - Highest levels of adverse effects have been seen with oral administration (over inhaled, intranasal, etc.)

4

What Factors Increase the Risk – Patient Specific Risks

- **Pathophysiologic Variables**
 - Liver and Kidney Function
- **Age and Sex**
 - More common in the very young or the very old.
 - More adverse drug reactions are reported in women than in men.
- **History of Allergy to Drugs**
 - Adverse reactions are always more likely in a patient who has had a history of previous trouble.
- **Individual Idiosyncrasy**
 - Factors such as enzymatic differences, muscle mass, etc.
 - Altered tissue responsiveness to a medication is likely hereditary.

5

What Factors Increase the Risk?

- Drug Interactions
 - Incidence of ADR's is directly related to the number of drugs administered.
 - Always important to specifically ask about social habits, supplements, etc.



6

Antimalarials

- hydroxychloroquine or Plaquenil
- hydroxychloroquine more common and less toxic than more effective chloroquine
- Common medication used by patient's who are suffering from rheumatoid arthritis
- usual dose is 200-400 mg/d @night with onset of action after a period of 24 months
- Primarily used to help manage pain and increase mobility, has a mild affect on slowing down joint destruction

7


Treatment and Management: Antimalarial Ocular Complications

- Have affinity for pigmented structures such as iris, choroid and RPE
- Toxic affect on the RPE and photoreceptors leading to rod and cone loss.
- Have slow excretion rate out of body with toxicity and functional loss continuing to occur despite drug discontinuation.

8

Question

Which of the following depicts a retina undergoing hydroxychloroquine toxicity?



ARMD

Macular Hole

OHS

Bull's Eye Maculopathy


9

Treatment and Management: Antimalarial Ocular Complications

- Toxicity can lead to whorl keratopathy, "bulls eye" maculopathy, retinal vessel attenuation, and optic disc pallor.
- Early stages of maculopathy are seen as mild stippling or mottling and reversible loss of foveal light reflex
- "Classic" maculopathy is in form of a "bulls eye" and is seen in later stages of toxicity
 - this is an irreversible damage to the retina despite discontinuation of medication

10

Treatment and Management: Antimalarials



Bulls Eye Maculopathy

Whorl Keratopathy

11

Fabry Disease

- alpha-galactosidase-A deficiency.
 - insufficient breakdown of lipids, which build up to harmful levels in the eyes, kidneys, autonomic nervous system, and cardiovascular system.
- Fabry disease is one of several lipid storage disorders and the only X-linked lipid storage disease.
- Lipid storage may lead to impaired arterial circulation and increased risk of heart attack or stroke.
 - The heart may also become enlarged and the kidneys may become progressively involved.
- Other signs include decreased sweating, fever, and gastrointestinal difficulties.

12

Revised Recommendations on Screening for Retinopathy

- 2002 recommendations for screening were published by Ophthalmology
- Revised recommendations on screening published in Ophthalmology 2011; 118:415-42
 - Significant changes in light of new data on the prevalence of retinal toxicity and sensitivity of new diagnostic techniques
 - Risk of toxicity after years of use is higher than previously believed
 - Risk of toxicity approaches 1% for patients who exceed 5 years of exposure

13

Revised Recommendations on Screening for Retinopathy

- Amsler grid testing removed as an acceptable screening technique
 - NOT equivalent to threshold VF testing
- Strongly advised that 10-2 VF screening be supplemented with sensitive objective tests such as:
 - Multifocal ERG
 - Spectral domain OCT
 - Fundus autofluorescence
- "Ideal" body weight versus "real weight" recommended for dosing and at <6.5 mg/kg

14


"New" New Recommendations

- **Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy –** Ophthalmology 2016; 123:1386-1394
 - Released March 2016 from American Academy of Ophthalmology
 - revised in light of new information about the prevalence of toxicity, risk factors, fundus distribution, and effectiveness of screening tools.

15

2016 Recommendations

- maximum daily HCQ use of 5.0 mg/kg real weight, which correlates better with risk than ideal weight.
- risk of toxicity is dependent on daily dose and duration of use.
 - at recommended doses:
 - risk of toxicity up to 5 years is under 1%
 - up to 10 years is under 2%
 - rises to almost 20% after 20 years. However, even after 20 years, a patient without toxicity has only a 4% risk of converting in the subsequent year.



16

2016 Recommendations

- High dose and long duration of use are the most significant risks.
 - Other major factors are concomitant renal disease, or use of tamoxifen
- A baseline fundus examination should be performed to rule out preexisting maculopathy.
- Begin annual screening after 5 years for patients on acceptable doses and without major risk factors.

17


2016 Recommendations

- primary screening tests are automated visual fields plus spectral-domain optical coherence tomography (SD OCT)
- most patients of Asian descent will show initial damage in a more peripheral extramacular distribution near the arcades (require a 24-2 as opposed to 10-2 and OCT scans need to be analyzed further out)

18

Revised Recommendations on Screening for Retinopathy


- Parafoveal loss of visual sensitivity may appear before changes are seen on fundus evaluation
 - Many instances where retinopathy was unrecognized for years as field changes were dismissed as “non-specific” until the damage was severe
 - 10-2 VF should always be repeated promptly when central or parafoveal changes are observed to determine if they are repeatable
 - Advanced toxicity shows well-developed paracentral scotoma



19


20

Paracentral Scotomas



21


Normal Retina: VF/OCT/ERG



Rodriguez-Padilla, J. A. et al. Arch Ophthalmol 2007;125:775-780. OPTHALMOLOGY PIL=PR Integrity Line


22

Mild Maculopathy



23

Bull's Eye Maculopathy



24

Major Risk Factors

Table 1. Major Risk Factors for Toxic Retinopathy

Daily dosage	
HCQ	>5.0 mg/kg real weight
CQ	>2.3 mg/kg real weight
Duration of use	>5 Yrs, assuming no other risk factors
Renal disease	Subnormal glomerular filtration rate
Concomitant drugs	Tamoxifen use
Macular disease	May affect screening and susceptibility to HCQ/CQ

CQ = chloroquine; HCQ = hydroxychloroquine.

25

Screening Recommendations

Table 2. Screening Frequency

Baseline Screening	Fundus examination within first year of use Add visual fields and SD OCT if maculopathy is present
Annual Screening	Begin after 5 yrs of use Sooner in the presence of major risk factors

SD OCT = spectral-domain optical coherence tomography.

26

Tetracyclines

- Drug of choice for Rocky Mountain Spotted Fever, Cholera, Lyme disease, mycoplasma pneumonia, and chlamydial infections.
- Side effects include gastric discomfort, effects on calcified tissues, vestibular problems.
- Should not be used in children under the age of 8 due to discoloration of teeth.

27

Tetracyclines

- This group includes:
 - Tetracycline (250mg - 500 mg cap BID,QID) needs to be taken 1 hour before or 2 hours after a meal.
 - Minocycline (100 mg cap BID)
 - Doxycycline (20mg - 100 mg cap or tab BID)
 - In Canada: Apprilon (30 mg doxy + 10 mg slow release doxy)
- Rules of Thumb with Doxy:
 - Do not take before lying down (>2 hours before)
 - Do not take with calcium and avoid antacids
 - Do not take with dairy
 - Do take with food

28

Tetracyclines: Ocular SE

- Systemic use of this group rarely causes serious SE.
- The most commonly reported SE is pseudotumor cerebri associated primarily with tetracycline and minocycline. Increased intracranial pressure is not dose dependent and may occur as early as 4 hours after first taking the drug or after many years of drug use.
- All tetracycline agents are photosensitizers.



29


Antianginal: Amiodarone

- Brand names: Cordarone, Pacerone
- Antiarrhythmic agent used in the treatment of atrial and ventricular tachcardias.
- Systemic adverse SE include: interstitial pulmonary fibrosis, GI intolerance, tremor, ataxia, dizziness, liver toxicity, photosensitivity, muscle weakness etc.
- After long-term use, more than 50% of Px have to discontinue use due to toxic responses.

30

Antianginal: Amiodarone Ocular SE

- corneal microdeposits occur in nearly all Px who are using the drug long-term
 - ▣ epithelial whorl-like pattern similar as seen in chloroquine treatment
 - ▣ horizontal, irregular branching line near the junction of the mid to outer 1/3rd of cornea



31

Antianginal: Amiodarone Ocular SE

- generally visible keratopathy develops in most Px within 6 weeks after drug initiation and reach peak within 3-6 months
- minimal deposition in Px on a dose of 100-200 mg/day though 400 mg or more will have all Px show deposit
- will see regression in 3-7 months after discontinuation
- other complications include:
 - ▣ decreased VA,
 - ▣ color vision defects,
 - ▣ photosensitivity,
 - ▣ dry eyes,
 - ▣ decreased corneal sensation,
 - ▣ optic neuropathy and
 - ▣ pseudotumor.

32

Antidepressants

- Includes:
 - ▣ Tricyclic antidepressant (TCA): amitriptyline, nortriptyline (Elavil, Levate) (inexpensive medication)
 - ▣ Selective serotonin re-uptake inhibitors (SSRI): fluoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft) (all of these are very expensive medications!)
 - ▣ monoamine oxidase (MAO): isocarboxazid (Marplan)

33


Antidepressants: Summary of Ocular Side Effects

- most of the side effects are transient, reversible, and cause little clinical significance
- most common side effects is blurring of vision which is generally mild and transient (improves with sustained use of medication)
- mydriasis can be a concern in patients with NAG or narrow angles
- diplopia and nystagmus have been reported though generally in patients who are currently using other agents such as lithium or diazepam
- increased symptoms of dry eye

37


Corticosteroids (Glucocorticoids)

- Glucocorticoids promote normal metabolism (e.g. gluconeogenesis, protein catabolism), increase resistance to stress, alter blood cell levels (e.g. decrease eosinophils, basophils, monocytes and lymphocytes), and have anti-inflammatory action.



38

Corticosteroids- Systemic SE




- Systemic administrations can result in:
 - ▣ Osteoporosis
 - ▣ Increased appetite
 - ▣ Emotional disturbances
 - ▣ Hypertension
 - ▣ Edema
 - ▣ Peptic ulcers
 - ▣ Increased risk of infection

39

Corticosteroids- Ocular SE

- Systemic use can result in:
 - ▣ PSC cataracts
 - ▣ Increased IOP
 - ▣ Delayed wound healing
 - ▣ Decreased resistance to infection
 - ▣ Visual hallucinations
 - ▣ Subconjunctival/retinal hemes and edema
 - ▣ Papilledema



40

Corticosteroids: Ocular SE

- Race is important as steroid induced glaucoma is more frequent in whites than blacks, and depigmentation from SC injection is more frequent in blacks.
- Steroid IOP responders tend to have more field loss than non-responders, more common in POAG and 1st degree relatives of POAG patients, higher risk in younger children and typically presents 4-6 weeks after initiation of steroid.
- Steroids affect all ocular structures resulting in development of steroid induced glaucoma, PSC cataracts, enhanced HSK infections, decreased wound healing, band keratopathy, etc.

41


Estrogen Receptor Antagonist-Tamoxifen

- Tamoxifen is used in the treatment of breast cancer (normal breast tissue stimulated to grow by estrogens, so estrogen antagonists can result in tumor regression)
- The most common adverse affects include: hot flashes, nausea, and vomiting. Menstrual irregularities and vaginal bleeding can also occur.

42

Estrogen Receptor Antagonist-Tamoxifen- Ocular SE

- Significant visual loss can occur with tamoxifen. Stopping Tx usually prevents further deterioration but may not result in visual recovery.
- Tamoxifen retinopathy characterized by presence of refractile bodies (due to axonal death).
- Additional findings may include CME, macular and peripheral retinal RPE changes, parafoveal hemes and subepithelial corneal deposits.



43


Antihistamines: Ocular SE

- Systemic use of the medications have a weak atropine action that accounts for the pupillary changes. With chronic use, anisocoria, decreased accommodation, and blurred vision can also occur.
- There has also been evidence to demonstrate a decrease in tear production making Px symptomatic for dry eyes and CL intolerance.

44

Tamsulosin (Flomax)

- Used to treat prostate enlargement and improve urinary flow in men (urologists are treating women with this drug).
- The well-known syndrome, intraoperative floppy iris syndrome, used to occur only in men but now has to be a concern for women who may also be taking the medication.
- Even if the drug is discontinued, the patient is at a lifetime risk of more complicated cataract surgery.



45

Isotretinoin


- Major Ocular Side Effect: Alteration of Meibomian Gland Secretions
 - Gland atrophy frequently develops which is beneficial for the treatment of acne, but harmful for the ocular surface.
 - Decreased Volume with Increased Thickness
 - Results in:
 - High levels of tear evaporation
 - Increased Tear Film Osmolarity
 - Ocular Discomfort
- Most Common Ocular Finding in 20-50%:
 - Blepharoconjunctivitis



52

Isotretinoin and Blepharoconjunctivitis


- Severity can vary, but may lead to corneal involvement and blurry vision.
- Nearly all patients will experience difficulty with Contact Lenses.
 - Need to reduce wearing time.
- Treatment is Artificial Tear Supplementation:
 - Which type would you recommend?



53

Retinoids/Isotretinoin

- Intracranial HTN (Pseudotumor Cerebri)
 - Can be caused by Vitamin A itself or the derivatives such as Isotretinoin.
 - Retinoids are one of the two main categories of drugs that result in increased intracranial pressure.
 - Second major drug class is the tetracycline derivatives, especially minocycline.
 - Risk increases if tetracyclines are used in combination with retinoids.



55

Ethambutol

- Bacteriostatic, antimycobacterial medication used in the treatment of tuberculosis.
- Recommended to be given in combination with first line treatment Isoniazid, Rifampin, and Pyridoxine until drug susceptibility has been determined.



56

Ethambutol

- Primary Ocular Manifestation: Retrobulbar Neuritis
 - Two forms resulting from toxicity:
 - Most Common: Central with loss of VA and color vision
 - Less Common: Peripherally with contraction of VF
- Also, can have retinal findings such as ONH swelling, hemes, and macular edema = RARE.
- MOA: Damage to the amacrine and bipolar cells (Not fully understood)
- Earliest finding is often loss of contrast sensitivity, followed by color vision.
 - Isoniazid is also known to cause optic neuritis, but in much less frequent numbers.



57

Ethambutol

- Deterioration will continue even if ethambutol is discontinued.
- Largely affected by dosage:
 - Recommended levels should not exceed 15 mg/kg daily.
 - Can tolerate higher levels for no longer than 2 months to prevent optic nerve damage.



58